Digital health smartphone company for respiratory disease, ResApp Health
(ASX:RAP) has announced positive top-line results from its Australian Breathe Easy adult clinical study.
ResApp’s smartphone-based algorithms were found to accurately diagnose all respiratory diseases included in the study: lower respiratory tract disease, pneumonia, asthma exacerbations, chronic obstructive pulmonary disease (COPD).
The study recruited 979 participants.
As many as 339 million people are estimated to have asthma.
The ability to identify a worsening of asthma symptoms due to infection or irritants, is an important part of effective asthma management plans.
Shares in ResApp Health
(ASX:RAP) closed flat at 12.5 cents on Thursday
